Atgam Market Report 2026

Atgam Market Overview

• The Atgam market growth in the historic period has been driven by clinical effectiveness in t cell suppression, established role in aplastic anemia • Market expansion is supported by increasing transplant procedure volumes, growing demand for targeted immunosuppression • Growth Driver: Growth Of The Atgam Market Driven By Rising Organ Transplantation Rate • Market Trend: Regulatory Update Enhances Labeling For Renal And Aplastic Anemia Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Atgam Market?

Atgam is a prescription medication made from antithymocyte globulin (equine), derived from horse serum, designed to suppress the immune system. It is mainly used to treat aplastic anemia and prevent organ transplant rejection by reducing the activity of T lymphocytes, key immune cells. Atgam helps to reduce the immune system's activity, thereby preventing it from attacking the transplanted organ or body tissues. The main types of clinical indications for atgam are renal transplant rejection and aplastic anemia. Atgam is an intravenous immunosuppressant used short-term to prevent acute renal transplant rejection by suppressing the immune system. It is distributed through various distribution channels, such as hospital pharmacies and retail pharmacies, and used by several end-users, including adult patients and geriatric patients.

What Is The Atgam Market Growth Forecast?

The growth in the forecast period can be attributed to increasing transplant procedure volumes, growing demand for targeted immunosuppression, expansion of hematology specialty care, improved supportive care frameworks, continued clinical guideline inclusion. Major trends in the forecast period include continued use in aplastic anemia treatment, growing role in transplant rejection management, expansion of immunosuppressive biologic therapies, improved outcomes in hematologic disorders, rising use in specialized transplant centers.

Global Atgam Market Segmentation

1) By Clinical Indication: Renal Transplant Rejection, Aplastic Anemia 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies 3) By End-User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Atgam Market?

The rise in the rate of organ transplantations is expected to propel the growth of the atgam market going forward. Organ transplantation is a surgical procedure where a diseased or dysfunctional organ in a patient is substituted with a healthy organ from a donor. The rise in organ transplantations can be attributed to several factors, such as chronic diseases, aging populations, increased research, and funding. Atgam (anti-thymocyte globulin) is used in organ transplantation to prevent acute rejection by targeting and depleting T-cells, reducing immune activity. It is often combined with other immunosuppressive drugs to enhance graft acceptance and improve outcomes. For instance, in January 2025, according to the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational organization, the US recorded 48,149 organ transplants in 2024, surpassing 48,000 and reflecting a 3.3% increase compared to 2023. Of these, 41,119 transplants were from deceased donors, while 7,030 were from living donors. Therefore, the rise in the rate of organ transplantations is driving the growth of the atgam industry. The increasing geriatric population is expected to propel the growth of the atgam market going forward. The geriatric population consists of individuals aged 65 and above, commonly regarded as elderly and often requiring specialized healthcare and assistance. Advancements in healthcare and medical technology have led to significant improvements in medical care, treatment options, and preventive measures that notably increased life expectancy, resulting in a growing elderly population. Atgam prevents organ rejection and manages autoimmune disorders in older adults, who are more vulnerable to immune-related complications. Modulating the immune system enhances transplant outcomes and contributes to an improved quality of life for the elderly. For instance, in October 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2030, it is projected that 1 in 6 people worldwide will be aged 60 years or older. The global population of individuals aged 60 and older is anticipated to grow significantly, rising to 1.4 billion by 2030. By 2050, this demographic is projected to reach 2.1 billion, effectively doubling the current figures. Additionally, the population of those aged 80 and above is expected to surge threefold during the same period, increasing to about 426 million by 2050. Therefore, the increasing geriatric population is driving the growth of the atgam industry.

Key Players In The Global Atgam Market

Major companies operating in the atgam market are Pfizer Inc.

Global Atgam Market Trends and Insights

Major companies operating in the atgam market are focusing on labeling supplements to maintain regulatory compliance, improve product transparency. Labeling supplements involves submitting updated clinical, safety, or pharmacokinetic data to regulatory authorities to ensure that product information remains current and accurately reflects emerging evidence. For instance, in February 2023, Pfizer Inc., a US-based multinational pharmaceutical company, submitted a Prior Approval Supplement (PAS) to update the pharmacokinetic (PK) data in the labeling of ATGAM (anti-thymocyte globulin [equine]) sterile solution. ATGAM treats renal allograft rejection and moderate to severe aplastic anemia. The supplement includes PK data from a study in Japanese adults with aplastic anemia, to be added under the Ethnicity section of the Pharmacokinetics label. The proposed revisions are largely acceptable, with some modifications.

Regional Insights

North America was the largest region in the atgam market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Atgam Market?

The atgam market consists of sales of the anti-thymocyte globulin (ATG). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Atgam Market Report 2026?

The atgam market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the atgam industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.